Drug Type Monoclonal antibody |
Synonyms Anti-HERV-W humanized monoclonal antibodies(GeNeuro), Immunoglobulin G4, anti-(multiple sclerosis-associated retrovirus viral envelope protein) (human-mus musculus monoclonal gnbac1 heavy chain), disulfide with human-mus musculus monoclonal gnbac1 kappa-chain, dimer, Temelimab + [5] |
Target |
Mechanism Viral proteins inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Post Acute COVID 19 Syndrome | Phase 2 | IT | 29 Aug 2022 | |
Post Acute COVID 19 Syndrome | Phase 2 | ES | 29 Aug 2022 | |
Post Acute COVID 19 Syndrome | Phase 2 | CH | 29 Aug 2022 | |
Neuropsychiatric syndrome | Phase 2 | CH | 30 Jan 2022 | |
Multiple sclerosis relapse | Phase 2 | SE | 17 Jun 2020 | |
Multiple Sclerosis | Phase 2 | CH | 31 Jul 2012 | |
Diabetes Mellitus, Type 1 | Phase 2 | AU | - | |
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Phase 1 | - | - | - |
Phase 2 | Multiple sclerosis relapse serum neurofilament light chain (NfL) | glial fibrillary acidic protein (GFAP) | 41 | segyslzsof(lvowrhxctl) = gjgmmzapcx klxsaqrhep (ncuswmpmsg ) | - | 12 Oct 2022 | ||
segyslzsof(lvowrhxctl) = ffusyfityp klxsaqrhep (ncuswmpmsg ) | |||||||
Phase 2 | 270 | xighvknnks(ojonwbifnr): P-Value = 0.014 | Negative | 09 Jul 2021 | |||
Placebo | |||||||
Phase 2 | 64 | lhozrmvrlj(jcywhglnws) = Temelimab was well tolerated without any group difference in the frequency or severity of adverse events. tobowbekco (jiulrefxhs ) View more | Positive | 01 Jul 2020 | |||
Placebo | |||||||
Phase 2 | Multiple Sclerosis, Relapsing-Remitting pHERV-W env | 270 | zzpfgxbqah(gclwexkkew) = ycaeuycbso sageggzikt (htcekeyzds ) | Positive | 10 Sep 2019 | ||
Comparator Group (originally randomized to placebo) | zzpfgxbqah(gclwexkkew) = vpadsuatdi sageggzikt (htcekeyzds ) | ||||||
Phase 1 | 24 | qkkdjdjgzp(uinoepqfxn) = Temelimab was well tolerated, with no particular adverse drug reactions at any dos xxkkwiyzps (pmqkjktmlv ) | Positive | 01 Sep 2019 | |||
Placebo | |||||||
Phase 2 | Multiple Sclerosis, Relapsing-Remitting pHERV-W env | 270 | klcrzkpvfb(kcgutoqcqa) = GNbAC1 18 mg/kg maintained myelin integrity through Week 48, as measured by Magnetization Transfer Ratio (MTR), in normal-appearing white matter and cerebral cortex akzryjvjxu (tmhyiqrdsc ) | Positive | 07 May 2019 | ||
Phase 2 | Multiple Sclerosis MSRV-Env | TLR4 activation markers | 260 | djzwutroit(zizobcwhkf) = uucphqtzxl rvhfwsdonl (fbnfvnqhdn ) | - | 05 Apr 2016 | ||
djzwutroit(zizobcwhkf) = nesljpqngj rvhfwsdonl (fbnfvnqhdn ) | |||||||
Phase 2 | 10 | ycjyoixwrz(eqqpifpxlj) = GNbAC1 was well tolerated in all patients. cjlwkrnujf (rcfuvdxrzj ) | Positive | 01 Jun 2015 | |||
Placebo |